Core Concepts
GLP-1 agonists can effectively reduce A1c levels and BMI in older patients with uncontrolled type 2 diabetes, potentially eliminating the need for additional medications.
Abstract
The study presented at the Gerontological Society of America's annual meeting focused on the impact of GLP-1 agonists on older patients with uncontrolled type 2 diabetes. Key highlights include:
- Reduction in A1c levels and BMI in participants aged 65-84.
- Education and counseling on diet and lifestyle modifications were provided.
- GLP-1 agonists led to a reduction in A1c levels to 5.8%-7.7% and BMI to 23-39.8.
- Deprescription of other medications like insulin and sulfonylureas was possible.
- GLP-1 agonists can induce remission of type 2 diabetes through weight loss.
- Weight loss and diabetes control offer cardiovascular protection in these patients.
Stats
Participants had initial A1c levels ranging from 9.6% to 12.6%.
BMI ranged from 27 to 48.2.
A reduction in A1c to 5.8% to 7.7% was observed.
BMI reduced to between 23 and 39.8.
Quotes
"The reduction in BMI that we saw in our patients even though they were still in the category of obesity produces a substantial benefit in the management [of type II diabetes]." - Anna Pendrey, MD
"You can induce remission of type 2 diabetes through weight loss that GLP-1s can cause." - Rodolfo Galindo, MD